Literature DB >> 14671813

[Problems of pharmacotherapy of infections in the aged].

A Kuhnke1, H Lode.   

Abstract

Infectious diseases play an important role in the elderly. Disease progression is often more severe, displaying a higher complication rate and causing increased mortality. Elderly patients suffer more frequently than younger under pneumonia, exacerbations of chronic bronchitis, urinary tract infections as well as skin and soft tissue infections. When starting empiric antibiotic therapy one should consider that the bacterial spectrum afflicting elderly patients may differ from that afflicting younger patients. In addition an increasing number of nosocomial and multiresistant pathogens is seen in elderly patients due to more frequent hospitalisation and living in nursing homes. Patient multimorbidity and multiple co-medications make awareness of important drug-interactions essential. The purpose of this article is to review the indications and side-effects of well-tried and newer antibiotics with respect to patients age. Especially the newer antibiotics Ertapenem, Linezolid, Quinupristin/Dalfopristin and Telithromycin are discussed in detail.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671813     DOI: 10.1007/s00108-003-0944-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

Review 1.  Ageing and infection.

Authors:  Gaëtan Gavazzi; Karl-Heinz Krause
Journal:  Lancet Infect Dis       Date:  2002-11       Impact factor: 25.071

Review 2.  Side effects of cephalosporins.

Authors:  S R Norrby
Journal:  Drugs       Date:  1987       Impact factor: 9.546

Review 3.  [Infection in the elderly--what is different?].

Authors:  H Werner; J Kuntsche
Journal:  Z Gerontol Geriatr       Date:  2000-10       Impact factor: 1.281

4.  Management of urinary tract infections in the elderly.

Authors:  I Beyer; A Mergam; F Benoit; C Theunissen; T Pepersack
Journal:  Z Gerontol Geriatr       Date:  2001-04       Impact factor: 1.281

Review 5.  Fluoroquinolones in the elderly: safety considerations.

Authors:  Ralf Stahlmann; Hartmut Lode
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 6.  Meropenem in elderly and renally impaired patients.

Authors:  B A Cunha
Journal:  Int J Antimicrob Agents       Date:  1998-05       Impact factor: 5.283

Review 7.  Bacterial skin infections in the elderly: diagnosis and treatment.

Authors:  Simone Laube; Anne M Farrell
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

Review 8.  Pharmacokinetic drug interactions of macrolides.

Authors:  P Periti; T Mazzei; E Mini; A Novelli
Journal:  Clin Pharmacokinet       Date:  1992-08       Impact factor: 6.447

9.  Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.

Authors:  Joseph S Solomkin; Albert E Yellin; Ori D Rotstein; Nicolas V Christou; E Patchen Dellinger; Jose M Tellado; Osvaldo Malafaia; Alvaro Fernandez; Kyuran A Choe; Alexandra Carides; Vilas Satishchandran; Hedy Teppler
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

10.  Ertapenem versus ceftriaxone followed by appropriate oral therapy for treatment of complicated urinary tract infections in adults: results of a prospective, randomized, double-blind multicenter study.

Authors:  Kevin M Tomera; Emmanuel A Burdmann; Oscar G Pamo Reyna; Qi Jiang; Wendy M Wimmer; Gail L Woods; Richard M Gesser
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.